Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit [Yahoo! Finance]
Coya Therapeutics, Inc. (COYA)
Company Research
Source: Yahoo! Finance
developing biologics intended to enhance regulatory T cell (Treg) function, announces that President and Chief Medical Officer Dr. Fred Grossman, D.O., FAPA will participate in the 3 rd Annual ALS Drug Development Summit being held May 21 – 23 at the Hyatt Regency in Boston. On May 21 from 11am – 1pm ET, Dr. Grossman will co-lead a workshop discussion titled, "Navigating the Hurdles of a Combination Therapy Approach & the Need to Demonstrate Efficacy on Top of Existing ALS Treatments" in Workshop B. On May 23 at 1:10pm ET, Dr. Grossman will give a presentation titled, "COYA 302: A Dual Mechanism Biologic Immunotherapy in the Treatment of ALS by Treg Activity to Reduce Inflammation." For more information on the 3 rd Annual ALS Drug Development Summit and to register, please visit: https://www.als-drug-development.com/ About Coya Therapeutics, Inc. Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing propri
Show less
Read more
Impact Snapshot
Event Time:
COYA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COYA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COYA alerts
High impacting Coya Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
COYA
News
- Why Coya Therapeutics Is A Smart Speculative Buy For Neurodegenerative Diseases [Seeking Alpha]Seeking Alpha
- Coya Therapeutics, Inc. (NASDAQ: COYA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $14.00 price target on the stock.MarketBeat
- Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium [Yahoo! Finance]Yahoo! Finance
- Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center SymposiumBusiness Wire
- Coya Therapeutics to Participate in the Mizuho Neuroscience SummitBusiness Wire
COYA
Sec Filings
- 3/29/24 - Form DEFA14A
- 3/28/24 - Form ARS
- 3/28/24 - Form DEFA14A
- COYA's page on the SEC website